Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 multiple-dose crossover study in adults with Fragile X syndrome
2007-005088-82Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mavoglurant in Fragile X syndrome (FXS) (2 arms), sponsored by Novartis. Primary endpoint: Change in global Aberrant Behavior Checklist – Community Edition (ABC-C) score. Started Nov 2007; status: completed.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2007-005088-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005088-82.